Intensive induction chemotherapy (IC) vs hypomethylating agents plus venetoclax (HMA/VEN) in IDH1-or IDH2-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study Meeting Abstract


Authors: Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, R. C.; Chen, E. C.; Ramos, J.; Stein, A. S.; DeAngelo, D. J.; Neuberg, D. S.; Stone, R. M.; Ball, B. J.; Stahl, M.
Abstract Title: Intensive induction chemotherapy (IC) vs hypomethylating agents plus venetoclax (HMA/VEN) in IDH1-or IDH2-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study
Meeting Title: 65th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 142
Issue: Suppl. 1
Meeting Dates: 2023 Dec 9-12
Meeting Location: San Deigo, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2023-11-02
Start Page: 1589
Language: English
ACCESSION: WOS:001159306706060
DOI: 10.1182/blood-2023-174283
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein